These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 27007392)

  • 1. n-3 Fatty Acid Supplementation and Leukocyte Telomere Length in Patients with Chronic Kidney Disease.
    Barden A; O'Callaghan N; Burke V; Mas E; Beilin LJ; Fenech M; Irish AB; Watts GF; Puddey IB; Huang RC; Mori TA
    Nutrients; 2016 Mar; 8(3):175. PubMed ID: 27007392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of n-3 fatty acids and coenzyme Q10 supplementation on neutrophil leukotrienes, mediators of inflammation resolution and myeloperoxidase in chronic kidney disease.
    Barden AE; Shinde S; Burke V; Puddey IB; Beilin LJ; Irish AB; Watts GF; Mori TA
    Prostaglandins Other Lipid Mediat; 2018 May; 136():1-8. PubMed ID: 29577973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prenatal omega-3 fatty acid supplementation does not affect offspring telomere length and F2-isoprostanes at 12 years: A double blind, randomized controlled trial.
    See VH; Mas E; Burrows S; O'Callaghan NJ; Fenech M; Prescott SL; Beilin LJ; Huang RC; Mori TA
    Prostaglandins Leukot Essent Fatty Acids; 2016 Sep; 112():50-5. PubMed ID: 27637341
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A randomized controlled trial of the effects of n-3 fatty acids on resolvins in chronic kidney disease.
    Mas E; Barden A; Burke V; Beilin LJ; Watts GF; Huang RC; Puddey IB; Irish AB; Mori TA
    Clin Nutr; 2016 Apr; 35(2):331-336. PubMed ID: 25908532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. n-3 fatty acids reduce plasma 20-hydroxyeicosatetraenoic acid and blood pressure in patients with chronic kidney disease.
    Barden AE; Burke V; Mas E; Beilin LJ; Puddey IB; Watts GF; Irish AB; Mori TA
    J Hypertens; 2015 Sep; 33(9):1947-53. PubMed ID: 26103129
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.
    Hodgson JM; Watts GF; Playford DA; Burke V; Croft KD
    Eur J Clin Nutr; 2002 Nov; 56(11):1137-42. PubMed ID: 12428181
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of a 12-week course of omega-3 polyunsaturated fatty acids on lipid parameters in hypertriglyceridemic adult HIV-infected patients undergoing HAART: a randomized, placebo-controlled pilot trial.
    Peters BS; Wierzbicki AS; Moyle G; Nair D; Brockmeyer N
    Clin Ther; 2012 Jan; 34(1):67-76. PubMed ID: 22212377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of [omega]3 fatty acids and coenzyme Q10 on blood pressure and heart rate in chronic kidney disease: a randomized controlled trial.
    Mori TA; Burke V; Puddey I; Irish A; Cowpland CA; Beilin L; Dogra G; Watts GF
    J Hypertens; 2009 Sep; 27(9):1863-72. PubMed ID: 19705518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enteral omega-3 fatty acid, gamma-linolenic acid, and antioxidant supplementation in acute lung injury.
    Rice TW; Wheeler AP; Thompson BT; deBoisblanc BP; Steingrub J; Rock P;
    JAMA; 2011 Oct; 306(14):1574-81. PubMed ID: 21976613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of eicosapentaenoic acid and docosahexaenoic acid on oxidative stress and inflammatory markers in treated-hypertensive type 2 diabetic subjects.
    Mori TA; Woodman RJ; Burke V; Puddey IB; Croft KD; Beilin LJ
    Free Radic Biol Med; 2003 Oct; 35(7):772-81. PubMed ID: 14583341
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Omega-3 fatty acids, oxidative stress, and leukocyte telomere length: A randomized controlled trial.
    Kiecolt-Glaser JK; Epel ES; Belury MA; Andridge R; Lin J; Glaser R; Malarkey WB; Hwang BS; Blackburn E
    Brain Behav Immun; 2013 Feb; 28():16-24. PubMed ID: 23010452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of Omega-3 fatty acid supplementation on markers of platelet and endothelial function in patients with peripheral arterial disease.
    Mackay I; Ford I; Thies F; Fielding S; Bachoo P; Brittenden J
    Atherosclerosis; 2012 Apr; 221(2):514-20. PubMed ID: 22296885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gamma-tocopherol and docosahexaenoic acid decrease inflammation in dialysis patients.
    Himmelfarb J; Phinney S; Ikizler TA; Kane J; McMonagle E; Miller G
    J Ren Nutr; 2007 Sep; 17(5):296-304. PubMed ID: 17720098
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The omega-3 fatty acids EPA and DHA decrease plasma F(2)-isoprostanes: Results from two placebo-controlled interventions.
    Mas E; Woodman RJ; Burke V; Puddey IB; Beilin LJ; Durand T; Mori TA
    Free Radic Res; 2010 Sep; 44(9):983-90. PubMed ID: 20540666
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Moderate oral supplementation with docosahexaenoic acid improves platelet function and oxidative stress in type 2 diabetic patients.
    Véricel E; Colas R; Calzada C; Lê QH; Feugier N; Cugnet C; Vidal H; Laville M; Moulin P; Lagarde M
    Thromb Haemost; 2015 Aug; 114(2):289-96. PubMed ID: 25832443
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of n-3 polyunsaturated fatty acids on leukotriene B₄ and leukotriene B₅ production from stimulated neutrophil granulocytes in patients with chronic kidney disease.
    Maaløe T; Schmidt EB; Svensson M; Aardestrup IV; Christensen JH
    Prostaglandins Leukot Essent Fatty Acids; 2011 Jul; 85(1):37-41. PubMed ID: 21530211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of n-3 fatty acids and exercise on oxidative stress parameters in type 2 diabetic: a randomized clinical trial.
    Fayh APT; Borges K; Cunha GS; Krause M; Rocha R; de Bittencourt PIH; Moreira JCF; Friedman R; da Silva Rossato J; Fernandes JR; Reischak-Oliveira A
    J Int Soc Sports Nutr; 2018; 15():18. PubMed ID: 29713249
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of fish oil supplementation on markers of inflammation in chronic kidney disease patients.
    Deike E; Bowden RG; Moreillon JJ; Griggs JO; Wilson RL; Cooke M; Shelmadine BD; Beaujean AA
    J Ren Nutr; 2012 Nov; 22(6):572-7. PubMed ID: 22285316
    [TBL] [Abstract][Full Text] [Related]  

  • 19. n-3 Fatty Acid Supplementation for the Treatment of Dry Eye Disease.
    ; Asbell PA; Maguire MG; Pistilli M; Ying GS; Szczotka-Flynn LB; Hardten DR; Lin MC; Shtein RM
    N Engl J Med; 2018 May; 378(18):1681-1690. PubMed ID: 29652551
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marine n-3 fatty acids, atrial fibrillation and QT interval in haemodialysis patients.
    Kirkegaard E; Svensson M; Strandhave C; Schmidt EB; Jørgensen KA; Christensen JH
    Br J Nutr; 2012 Mar; 107(6):903-9. PubMed ID: 21791142
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.